These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 16264105)
1. Bisphosphonates in metastatic bone disease: renal safety matters. Body JJ Oncologist; 2005; 10 Suppl 1():1-2. PubMed ID: 16264105 [No Abstract] [Full Text] [Related]
2. Preclinical perspectives on bisphosphonate renal safety. Body JJ; Pfister T; Bauss F Oncologist; 2005; 10 Suppl 1():3-7. PubMed ID: 16264106 [TBL] [Abstract][Full Text] [Related]
3. Bisphosphonates--role in cancer therapies. Mehrotra B J Oral Maxillofac Surg; 2009 May; 67(5 Suppl):19-26. PubMed ID: 19371811 [No Abstract] [Full Text] [Related]
4. The benefits and costs of bisphosphonates. Coleman RE J Support Oncol; 2007; 5(10):483-4. PubMed ID: 18240670 [No Abstract] [Full Text] [Related]
5. Concurrent application of bisphosphonates and external beam radiotherapy in patients with metastatic bone disease from renal cancer. Vassiliou V; Leotsinides M; Kalogeropoulou C; Kardamakis D BJU Int; 2009 Aug; 104(3):417-8; author reply 418. PubMed ID: 19614659 [No Abstract] [Full Text] [Related]
6. Adverse effects of bisphosphonates: current issues. Diel IJ; Bergner R; Grötz KA J Support Oncol; 2007; 5(10):475-82. PubMed ID: 18240669 [TBL] [Abstract][Full Text] [Related]
7. Case 2. Osteonecrosis of the jaws associated with bisphosphonate therapy. Mignogna MD; Fedele S; Lo Russo L; Ciccarelli R; Lo Muzio L J Clin Oncol; 2006 Mar; 24(9):1475-7. PubMed ID: 16549843 [No Abstract] [Full Text] [Related]
8. [Treatment of bone metastases with bisphosphonates]. Gremaud M; Delouche D; Monnerat C Rev Med Suisse; 2006 Aug; 2(75):1861-6. PubMed ID: 16948423 [TBL] [Abstract][Full Text] [Related]
9. On the horizon: can bisphosphonates prevent bone metastases? Coleman R Breast; 2007 Dec; 16 Suppl 3():S21-7. PubMed ID: 17988867 [TBL] [Abstract][Full Text] [Related]
10. [Treatments of metastases in cancer]. Gligorov J; Launay-Vacher V; Aapro M Bull Cancer; 2012 Mar; 99(3):333-43. PubMed ID: 22133711 [TBL] [Abstract][Full Text] [Related]
11. Bisphosphonates for care and cure. Body JJ Eur J Cancer; 2009 Sep; 45 Suppl 1():396-7. PubMed ID: 19775644 [No Abstract] [Full Text] [Related]
13. Pharmacotherapy of bone metastases in breast cancer patients. Petrut B; Simmons C; Broom R; Trinkaus M; Clemons M Expert Opin Pharmacother; 2008 Apr; 9(6):937-45. PubMed ID: 18377337 [TBL] [Abstract][Full Text] [Related]
14. [Current use of bisphosphonates in clinical oncology]. Vrbanec D; Plestina S; Belev B; Unusić J; Pavlinić-Diminić V Lijec Vjesn; 1999; 121(9-10):296-301. PubMed ID: 19658372 [TBL] [Abstract][Full Text] [Related]
15. Bisphosphonates for breast cancer: questions answered, questions remaining. Layman R; Olson K; Van Poznak C Hematol Oncol Clin North Am; 2007 Apr; 21(2):341-67. PubMed ID: 17512453 [TBL] [Abstract][Full Text] [Related]
17. Bisphosphonate treatment recommendations for oncologists. von Moos R Oncologist; 2005; 10 Suppl 1():19-24. PubMed ID: 16264109 [TBL] [Abstract][Full Text] [Related]
18. Clinical efficacy and safety of zoledronic acid in prostate and breast cancer. Doggrell SA Expert Rev Anticancer Ther; 2009 Sep; 9(9):1211-8. PubMed ID: 19761424 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of zoledronic acid in patients with breast cancer metastatic to bone: a multicenter clinical trial. Cartenì G; Bordonaro R; Giotta F; Lorusso V; Scalone S; Vinaccia V; Rondena R; Amadori D Oncologist; 2006; 11(7):841-8. PubMed ID: 16880243 [TBL] [Abstract][Full Text] [Related]
20. Bisphosphonates and metastatic bone disease. Barni S; Mandalà M; Cazzaniga M; Cabiddu M; Cremonesi M Ann Oncol; 2006 Mar; 17 Suppl 2():ii91-95. PubMed ID: 16608996 [No Abstract] [Full Text] [Related] [Next] [New Search]